Tenaya Therapeutics (NASDAQ:TNYA) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a research note issued to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $18.00 target price on the stock.

Several other research analysts have also recently weighed in on the company. Chardan Capital reaffirmed a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th. Leerink Partners restated an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Piper Sandler reaffirmed an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $17.33.

Tenaya Therapeutics Trading Down 4.7 %

Shares of NASDAQ:TNYA opened at $1.43 on Tuesday. The company has a 50 day moving average of $2.28 and a 200-day moving average of $2.46. The firm has a market cap of $113.29 million, a P/E ratio of -0.99 and a beta of 2.89. Tenaya Therapeutics has a twelve month low of $0.99 and a twelve month high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last released its earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07. Equities research analysts forecast that Tenaya Therapeutics will post -1.35 EPS for the current year.

Institutional Trading of Tenaya Therapeutics

A number of hedge funds have recently bought and sold shares of the company. abrdn plc purchased a new position in shares of Tenaya Therapeutics in the third quarter worth approximately $1,063,000. Jacobs Levy Equity Management Inc. grew its position in Tenaya Therapeutics by 204.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock worth $651,000 after purchasing an additional 226,466 shares in the last quarter. Renaissance Technologies LLC raised its stake in Tenaya Therapeutics by 144.1% during the 2nd quarter. Renaissance Technologies LLC now owns 157,460 shares of the company’s stock valued at $488,000 after purchasing an additional 92,960 shares during the period. Wellington Management Group LLP raised its stake in Tenaya Therapeutics by 35.6% during the 3rd quarter. Wellington Management Group LLP now owns 294,133 shares of the company’s stock valued at $568,000 after purchasing an additional 77,235 shares during the period. Finally, Integral Health Asset Management LLC lifted its holdings in shares of Tenaya Therapeutics by 3.3% in the second quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company’s stock valued at $7,208,000 after purchasing an additional 75,000 shares in the last quarter. 90.54% of the stock is owned by hedge funds and other institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.